Alto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have been given an average rating of “Moderate Buy” by the eleven analysts that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $37.25.

A number of research analysts recently weighed in on ANRO shares. Wall Street Zen upgraded Alto Neuroscience from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. BTIG Research boosted their target price on Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Bank of America began coverage on shares of Alto Neuroscience in a research report on Tuesday, May 5th. They set a “buy” rating and a $35.00 target price for the company. Robert W. Baird cut their price target on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. Finally, Wolfe Research initiated coverage on shares of Alto Neuroscience in a research report on Friday, May 22nd. They set an “outperform” rating on the stock.

Alto Neuroscience Trading Down 0.7%

NYSE ANRO opened at $36.28 on Friday. Alto Neuroscience has a 12 month low of $3.41 and a 12 month high of $37.48. The company has a 50-day moving average of $28.53 and a 200-day moving average of $24.04. The company has a debt-to-equity ratio of 0.07, a current ratio of 14.85 and a quick ratio of 14.85. The company has a market cap of $1.42 billion, a P/E ratio of -14.99 and a beta of 1.06.

Alto Neuroscience (NYSE:ANRO) last released its earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.08. As a group, equities analysts predict that Alto Neuroscience will post -2.68 earnings per share for the current year.

Institutional Investors Weigh In On Alto Neuroscience

A number of large investors have recently modified their holdings of the stock. AQR Capital Management LLC acquired a new stake in Alto Neuroscience in the first quarter valued at approximately $52,000. Torren Management LLC bought a new stake in shares of Alto Neuroscience in the 4th quarter worth about $62,000. Invesco Ltd. bought a new position in shares of Alto Neuroscience during the first quarter worth about $67,000. Bridgeway Capital Management LLC lifted its position in shares of Alto Neuroscience by 85.9% during the second quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock worth $119,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Balyasny Asset Management L.P. acquired a new position in Alto Neuroscience in the fourth quarter worth about $198,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.